Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Single-inhaler triple therapy ups survival in COPD

Pearl Toh
29 Apr 2020

A once-daily triple therapy of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; ICS/LAMA/LABA*) in a single inhaler significantly reduces the risk of all-cause mortality compared with a dual therapy of UMEC/VI (LAMA/LABA) in chronic obstructive pulmonary disease (COPD) patients with a history of moderate or severe exacerbations, confirm the latest results of the IMPACT** study. 

Previously published data from the primary analyses have shown significant benefits with the triple therapy, including reductions in moderate/severe exacerbations, COPD hospitalization, death risk, and improved lung function and HRQoL***. However, data from 5.5 percent of the patients were censored from the previous analysis due to lack of vital status information for all-cause mortality. [N Engl J Med 2018;378:1671-1680]

The current analysis was performed following the collection of additional data on vital status at week 52, representing 99.6 percent of the intention-to-treat population. [Am J Respir Crit Care Med 2020;doi:10.1164/rccm.201911-2207OC]

“Because the number of missing patients exceeded the numbers of deaths in the study we felt caution was warranted in the interpretation of the original published findings,” said lead author Dr David Lipson from the Perelman School of Medicine, University of Pennsylvania in Philadelphia, Pennsylvania, US. “These new repeat analyses demonstrate the robustness of the original finding.”

In the phase III, double-blind, multicentre IMPACT study, 10,355 patients (mean age 65.3 years, 66 percent male) with COPD were randomized to FF/UMEC/VI (100/62.5/25 μg), FF/VI (100/25 μg), or UMEC/VI (62.5/25 μg) in a 2:2:1 ratio.

Treatment with triple therapy led to significantly reduced risk of all-cause mortality at 52 weeks (hazard ratio [HR], 0.72; p=0.042) compared with dual therapy containing UMEC/VI. While death risk was also reduced with triple therapy when compared with the ICS/LABA FF/VI, the difference between groups was not statistically significant (HR, 0.89; p=0.387).

“We believe that the mortality finding with FF/UMEC/VI compared to UMEC/VI was primarily driven by the steroid component and its effect on reducing exacerbations, especially hospitalized exacerbations,” said Lipson.

“[As] frequently exacerbating patients are at higher risk of hospitalization and death, these are the patients who appear to achieve the greatest survival benefit with once-daily FF/UMEC/VI triple therapy,” he explained.

Independent adjudicated results revealed that the triple therapy arm also had lower rates of death due to cardiovascular or respiratory causes as well as COPD-related death.

According to the researchers, this is the first trial to demonstrate a survival benefit with a pharmacologic therapy in COPD patients. Thus far, only smoking cessation, lung volume reduction surgery, and oxygen therapy in select patients have been shown to improve survival in these patients.  

“The data from patients [originally on triple therapy when entering the trial; 40 percent] … suggest that maintenance on a triple therapy is associated with a trend towards lower risk of death than step down to either dual therapy,” noted Lipson and co-authors.

“This supports the benefit of both ICS and LAMA in this population, and is of importance as international treatment guidelines suggest consideration of step down of therapy in stable patients,” they added. “However, our findings suggest that physicians should use caution when considering step down in therapy in patients with characteristics that mirror those enrolled in IMPACT.”

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).